Actively Recruiting
Improved Prescribing for Older Nursing Home Patients
Led by Amsterdam UMC, location VUmc · Updated on 2024-12-12
450
Participants Needed
7
Research Sites
63 weeks
Total Duration
On this page
Sponsors
A
Amsterdam UMC, location VUmc
Lead Sponsor
Z
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborating Sponsor
AI-Summary
What this Trial Is About
Research aim: To investigate the effect of training health care professionals in medication assessments on the medication use of nursing home residents with a limited life expectancy (\< 1.5-2 years). The core of the training is to tailor medication use to (palliative) treatment goals of nursing home residents. Design: A cluster randomized controlled trial on long term care wards in nursing homes, with the nursing home care organisations as unit of randomisation. The investigators intent to include 6 organisations and 450 nursing home patients. The research starts in september and lasts 1 year and 3 months. Eligible patients are nursing home patients of 65 years and older with a limited life expectancy (\< 1.5-2 year) of long term care wards. Intervention: The intervention includes a method in which healthcare professionals (medical practitioner, pharmacist and care worker) are trained to tailor medication to the (palliative) treatment goals of nursing home patients with a limited life expectancy. The training consists of 2 components: 1) medication assessment, and 2) advance care planning (ACP). In the intervention group, healthcare professionals receive the training in combination with supporting tools and educational materials, in the control group care continues as normal. The allocation ratio for control and intervention groups is 1:1. A process evaluation will take place simultaneously with the intervention study. Data collection takes place before the start of the intervention (T0), after 6 months (T1) and after 12 months (T2). Outcome measures: The primary outcome measure is potential under- and over-treatment with medication. The secondary outcome measure is experienced involvement in decision-making (measured with a short questionnaire based on the revised PATD (patients' attitude towards deprescribing)). Tertiary outcome measures are: quality of life, deaths, falls, hospital admissions/acute first aid referrals and pain. Discussion: The intervention is expected to result in a decrease in chronic and preventive medication prescriptions, an increase in medication for symptom treatment and more involvement (and satisfaction) of the nursing home resident in decision-making, without adverse effects.
CONDITIONS
Official Title
Improved Prescribing for Older Nursing Home Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Nursing home patients aged 65 years and above
- Living in long-term care wards in nursing homes
- Resident in a long-term care ward for at least 4 weeks before study start
You will not qualify if you...
- Temporary nursing home patients (such as those in geriatric rehabilitation or hospice care)
- Life expectancy less than 4 weeks
- Life expectancy clearly more than 1.5 to 2 years (for example, patients with Huntington's disease)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Zorggroep Apeldoorn, location Randerode, De Hofstede and De Windkanter
Apeldoorn, Gelderland, Netherlands, 7334DV
Active, Not Recruiting
2
Zorggroep Noordwest-Veluwe, locaties Weideheem en de Arcade
Harderwijk, Gelderland, Netherlands, 3844 JW
Active, Not Recruiting
3
Cordaan, location Nieuw Vredenburgh
Amsterdam, North Holland, Netherlands, 1057 DZ
Actively Recruiting
4
Amaris, Location Alporti and Rubina
Hilversum, North Holland, Netherlands, 1215 SE
Active, Not Recruiting
5
AxionContinu, location Isselwaerde and de Schutse
IJsselstein, Utrecht, Netherlands, 3401 BN
Actively Recruiting
6
Zorgspectrum, location de Plataan
Vianen, Utrecht, Netherlands, 4133 GX
Actively Recruiting
7
Dignis, location de Veldspaat
Groningen, Netherlands, 9743XV
Active, Not Recruiting
Research Team
M
Marlies Dijk, MD
CONTACT
E
Eefje Sizoo, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here